{"organizations": [], "uuid": "b1ef407466210267e08365eb39305f26d4b8cc77", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/11", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/10/globe-newswire-coherus-biosciences-reports-corporate-highlights-and-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Coherus BioSciences Reports Corporate Highlights and 2018 Financial", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-11T00:01:00.000+03:00", "replies_count": 0, "uuid": "b1ef407466210267e08365eb39305f26d4b8cc77"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/10/globe-newswire-coherus-biosciences-reports-corporate-highlights-and-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Coherus BioSciences Reports Corporate Highlights and 2018 Financial", "locations": [], "entities": {"persons": [{"name": "burke", "sentiment": "none"}], "locations": [{"name": "redwood city", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "humira", "sentiment": "none"}], "organizations": [{"name": "coherus biosciences, inc.", "sentiment": "neutral"}, {"name": "amgen inc", "sentiment": "none"}, {"name": "united states district court for the district of delaware", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "REDWOOD CITY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2018.\nFirst Quarter 2018 Corporate Highlights Include:\nOncology therapeutic franchise:\nCHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) Announced on March 26, 2018, that Judge Stark of the United States District Court for the District of Delaware adopted Magistrate Judge Burke’s Report and Recommendation to grant the motion of Coherus BioSciences, Inc. to dismiss with prejudice the patent infringement complaint alleging infringement of U.S. Patent No. 8,273,707 filed by Amgen Inc.\nFirst Quarter 2018 Financial Results:\nResearch and development (R&D) expenses for the first quarter of 2018 were $25.5 million compared to $53.8 million for the same period in 2017. The decrease in R&D expenses in the first quarter over the same period in 2017 was mainly due to the completion of our clinical trials for the immunology biosimilar drug candidates, CHS-1420 (adalimumab (Humira®) biosimilar) and CHS-0214 (etanercept (Enbrel®) biosimilar), and the reprioritization of resources to advance CHS-1701. General and administrative (G&A) expenses for the first quarter of 2018 were $16.6 million, compared to $18.8 million for the same period in 2017. The decrease in G&A expenses in 2018 was mainly attributable to a decrease in personnel and in certain legal and consulting services as a result of cost control steps taken since June 2017. Net loss attributable to Coherus for the first quarter of 2018 was ($44.3) million, or ($0.74) per share, compared to a net loss of ($74.8) million, or ($1.54) per share, for the same period in 2017. Cash and cash equivalents and investments in marketable securities – totaled $95.2 million as of March 31, 2018, compared to $126.9 million as of December 31, 2017.\nGuidance for 2018:\nCHS-1701 (pegfilgrastim (Neulasta®) biosimilar)\nAnticipate acceptance of the biologics license application (BLA) on or before June 3, 2018 and a U.S. Food and Drug Administration (FDA) action date of November 3, 2018. Anticipate European approval opinion on or before June 28, 2018. Commercial partnering discussions are projected to continue for certain ex-U.S. territories. Anticipate U.S. commercial launch directly following the potential FDA action date, dependent on regulatory review and approval timing.\nCHS-3351 (ranibizumab (Lucentis®) biosimilar) and CHS-2020 (aflibercept (Eylea®) biosimilar)\nInitiate clinical development of CHS-3351. Continue preclinical development of CHS-2020.\nCHS-1420 (adalimumab (Humira®) biosimilar)\nPursue manufacturing objectives in support of a BLA. Continue to develop partnering options pursuant to a 2022 launch.\nCash flow\nAnticipate cash use in operations of approximately $32 to $37 million for the second quarter of 2018.\nConference Call Information\nWhen: Thursday, May 10, 2018 at 4:30 p.m. ET\nDial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)\nConference ID: 2767588\nWebcast: http://investors.coherus.com\nPlease join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.\nAbout Coherus BioSciences, Inc.\nCoherus is a U.S. based integrated development and commercialization biologics company, focused on biosimilars. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Our team is composed of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development. Coherus is advancing CHS-1701 (pegfilgrastim biosimilar) towards commercialization, and has completed Phase 3 clinical programs for two anti-TNF product candidates, CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar). Coherus is also developing an early stage pipeline of ophthalmology biosimilar product candidates. For additional information, please visit www.coherus.com .\nForward-Looking Statements\nExcept for the historical information contained herein, the matters set forth in this press release are within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ expectations regarding acceptance of the BLA and the FDA’s action date; Coherus’ expectations regarding market approval in the U.S. and Europe; Coherus’ ability to enter into commercial collaborations in ex-U.S. territories; Coherus’ plan to initiate U.S. commercial launch for CHS-1701; Coherus’ plan to initiate the clinical development of CHS-3351; Coherus’ expectation to continue the preclinical development of CHS-2020; Coherus’ ability to pursue manufacturing objectives of CHS-1420 in support of a BLA; Coherus’ plan to continue to develop partnering options of CHS-1420; and Coherus’ ability to anticipate cash use for the second quarter of 2018. Such involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the . Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ biosimilar drug candidates; and the risks and uncertainties of possible patent litigation. All contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any . For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these , as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the three months ended March 31, 2018, filed with the Securities and Exchange Commission on May 10, 2018 and its future periodic reports to be filed with the Securities and Exchange Commission. Our results for the quarter ended March 31, 2018 are not necessarily indicative of our operating results for any future periods.\nEnbrel® and Neulasta® are registered trademarks of Amgen Inc.\nHumira® is a registered trademark of AbbVie Inc.\nLucentis® is a registered trademark of Genentech, Inc.\nEylea ® is a registered trademark of Regeneron Pharmaceuticals, Inc.\nCoherus BioSciences, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended March 31, 2018 2017 (unaudited) Revenue: Collaboration and license revenue $ - $ 161 Operating expenses: Research and development 25,455 53,775 General and administrative 16,577 18,803 Total operating expenses 42,032 72,578 Loss from operations (42,032 ) (72,417 ) Interest expense (2,408 ) (2,376 ) Other income (expense), net 138 (29 ) Net loss (44,302 ) (74,822 ) Net loss attributable to non-controlling interest 5 44 Net loss attributable to Coherus $ (44,297 ) $ (74,778 ) Net loss per share attributable to Coherus, basic and diluted $ (0.74 ) $ (1.54 ) Weighted-average number of shares used in computing net\nloss per share attributable to Coherus, basic and diluted 60,122,050 48,711,958\nCoherus BioSciences, Inc. Condensed Consolidated Balance Sheets (in thousands) March 31, December 31, 2018 2017 (unaudited) Assets Cash and cash equivalents $ 82,021 $ 126,911 Investments in marketable securities - short-term 13,143 - Other assets 33,298 35,700 Total assets $ 128,462 $ 162,611 Liabilities and Stockholders’ Equity (Deficit) Convertible notes $ 76,474 $ 76,206 Convertible notes-related parties 25,492 25,402 Other liabilities 29,584 30,468 Total stockholders' equity (deficit) (3,088 ) 30,535 Total liabilities and stockholders’ equity (deficit) $ 128,462 $ 162,611 CONTACT:\nPatrick O’Brien\nSenior Vice President, Investor Relations\nCoherus BioSciences, Inc.\npobrien@coherus.com\n+1 (650) 649-3527\nSource:Coherus BioSciences, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=75y6_6rD4QpCbnLwAR3DqbZgymwBHuqSSKAxXscufg_bUPcpv2DkhcbU75SCjQOMCU8lrThxsbFDa0y8LPuVN1JfW8IMA1cCthEM7KsteBk=", "https://www.globenewswire.com/Tracker?data=MrEN2HJQ7ujnpQt5jE01BJ95foQ5MkS6Va-xyw4d3UlyumRe_E6cN_0Lb_avxwk9fcn6YLyAdm0H222CqjIs1g==", "https://www.globenewswire.com/Tracker?data=omZ7toHj1kzVhg_lYnD2F2_o85SdNuuoT5zlwvjk3ZFJ5nOq-libGbS_C3hvDuAGqyuylnfrSXfdVFl4vgV-ONNppD_yKnr_QwEmuAFa5shReU-FYPsgqk0v1YBs2W7yqQe4lc0bjpYIwvnhcplBCavJK1lcs4-HxSaa5jkjHzoVA2yroFSyfA430KjpOjUi7_NPTBshJnyq1x3yLng_mA==", "https://www.globenewswire.com/Tracker?data=aA8vEn4Z2ffIu2D6b6M2-cN_tZ6E_0_CeExOxZdLit1CdrfmqEWRnt74w0TWKvjCGIyUVbc1QJJR1OGC0TeIZZcmDn3gz0snq4yjQ3keivk=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/37b5e3e4-4132-49a4-a83a-94920550245f"], "published": "2018-05-11T00:01:00.000+03:00", "crawled": "2018-05-11T00:40:38.010+03:00", "highlightTitle": ""}